Development of a stress response therapy targeting aggressive prostate cancer

Hao G. Nguyen, Crystal S. Conn, Yae Kye, Lingru Xue, Craig M. Forester, Janet E. Cowan, Andrew C. Hsieh, John T. Cunningham, Charles Truillet, Feven Tameire, Michael J. Evans, Christopher P Evans, Joy C. Yang, Byron Hann, Constantinos Koumenis, Peter Walter, Peter R. Carroll, Davide Ruggero

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Oncogenic lesions up-regulate bioenergetically demanding cellular processes, such as protein synthesis, to drive cancer cell growth and continued proliferation. However, the hijacking of these key processes by oncogenic pathways imposes onerous cell stress that must be mitigated by adaptive responses for cell survival. The mechanism by which these adaptive responses are established, their functional consequences for tumor development, and their implications for therapeutic interventions remain largely unknown. Using murine and humanized models of prostate cancer (PCa), we show that one of the three branches of the unfolded protein response is selectively activated in advanced PCa. This adaptive response activates the phosphorylation of the eukaryotic initiation factor 2-α (P-eIF2α) to reset global protein synthesis to a level that fosters aggressive tumor development and is a marker of poor patient survival upon the acquisition of multiple oncogenic lesions. Using patient-derived xenograft models and an inhibitor of P-eIF2α activity, ISRIB, our data show that targeting this adaptive brake for protein synthesis selectively triggers cytotoxicity against aggressive metastatic PCa, a disease for which presently there is no cure.

Original languageEnglish (US)
Article numbereaar2036
JournalScience Translational Medicine
Volume10
Issue number439
DOIs
StatePublished - May 2 2018

Fingerprint

Eukaryotic Initiation Factor-2
Prostatic Neoplasms
Phosphorylation
Unfolded Protein Response
Neoplasms
Proteins
Heterografts
Cell Survival
Up-Regulation
Therapeutics
Survival
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nguyen, H. G., Conn, C. S., Kye, Y., Xue, L., Forester, C. M., Cowan, J. E., ... Ruggero, D. (2018). Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine, 10(439), [eaar2036]. https://doi.org/10.1126/scitranslmed.aar2036

Development of a stress response therapy targeting aggressive prostate cancer. / Nguyen, Hao G.; Conn, Crystal S.; Kye, Yae; Xue, Lingru; Forester, Craig M.; Cowan, Janet E.; Hsieh, Andrew C.; Cunningham, John T.; Truillet, Charles; Tameire, Feven; Evans, Michael J.; Evans, Christopher P; Yang, Joy C.; Hann, Byron; Koumenis, Constantinos; Walter, Peter; Carroll, Peter R.; Ruggero, Davide.

In: Science Translational Medicine, Vol. 10, No. 439, eaar2036, 02.05.2018.

Research output: Contribution to journalArticle

Nguyen, HG, Conn, CS, Kye, Y, Xue, L, Forester, CM, Cowan, JE, Hsieh, AC, Cunningham, JT, Truillet, C, Tameire, F, Evans, MJ, Evans, CP, Yang, JC, Hann, B, Koumenis, C, Walter, P, Carroll, PR & Ruggero, D 2018, 'Development of a stress response therapy targeting aggressive prostate cancer', Science Translational Medicine, vol. 10, no. 439, eaar2036. https://doi.org/10.1126/scitranslmed.aar2036
Nguyen, Hao G. ; Conn, Crystal S. ; Kye, Yae ; Xue, Lingru ; Forester, Craig M. ; Cowan, Janet E. ; Hsieh, Andrew C. ; Cunningham, John T. ; Truillet, Charles ; Tameire, Feven ; Evans, Michael J. ; Evans, Christopher P ; Yang, Joy C. ; Hann, Byron ; Koumenis, Constantinos ; Walter, Peter ; Carroll, Peter R. ; Ruggero, Davide. / Development of a stress response therapy targeting aggressive prostate cancer. In: Science Translational Medicine. 2018 ; Vol. 10, No. 439.
@article{20225c4818ea40fe8bf0965e17e84e23,
title = "Development of a stress response therapy targeting aggressive prostate cancer",
abstract = "Oncogenic lesions up-regulate bioenergetically demanding cellular processes, such as protein synthesis, to drive cancer cell growth and continued proliferation. However, the hijacking of these key processes by oncogenic pathways imposes onerous cell stress that must be mitigated by adaptive responses for cell survival. The mechanism by which these adaptive responses are established, their functional consequences for tumor development, and their implications for therapeutic interventions remain largely unknown. Using murine and humanized models of prostate cancer (PCa), we show that one of the three branches of the unfolded protein response is selectively activated in advanced PCa. This adaptive response activates the phosphorylation of the eukaryotic initiation factor 2-α (P-eIF2α) to reset global protein synthesis to a level that fosters aggressive tumor development and is a marker of poor patient survival upon the acquisition of multiple oncogenic lesions. Using patient-derived xenograft models and an inhibitor of P-eIF2α activity, ISRIB, our data show that targeting this adaptive brake for protein synthesis selectively triggers cytotoxicity against aggressive metastatic PCa, a disease for which presently there is no cure.",
author = "Nguyen, {Hao G.} and Conn, {Crystal S.} and Yae Kye and Lingru Xue and Forester, {Craig M.} and Cowan, {Janet E.} and Hsieh, {Andrew C.} and Cunningham, {John T.} and Charles Truillet and Feven Tameire and Evans, {Michael J.} and Evans, {Christopher P} and Yang, {Joy C.} and Byron Hann and Constantinos Koumenis and Peter Walter and Carroll, {Peter R.} and Davide Ruggero",
year = "2018",
month = "5",
day = "2",
doi = "10.1126/scitranslmed.aar2036",
language = "English (US)",
volume = "10",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "439",

}

TY - JOUR

T1 - Development of a stress response therapy targeting aggressive prostate cancer

AU - Nguyen, Hao G.

AU - Conn, Crystal S.

AU - Kye, Yae

AU - Xue, Lingru

AU - Forester, Craig M.

AU - Cowan, Janet E.

AU - Hsieh, Andrew C.

AU - Cunningham, John T.

AU - Truillet, Charles

AU - Tameire, Feven

AU - Evans, Michael J.

AU - Evans, Christopher P

AU - Yang, Joy C.

AU - Hann, Byron

AU - Koumenis, Constantinos

AU - Walter, Peter

AU - Carroll, Peter R.

AU - Ruggero, Davide

PY - 2018/5/2

Y1 - 2018/5/2

N2 - Oncogenic lesions up-regulate bioenergetically demanding cellular processes, such as protein synthesis, to drive cancer cell growth and continued proliferation. However, the hijacking of these key processes by oncogenic pathways imposes onerous cell stress that must be mitigated by adaptive responses for cell survival. The mechanism by which these adaptive responses are established, their functional consequences for tumor development, and their implications for therapeutic interventions remain largely unknown. Using murine and humanized models of prostate cancer (PCa), we show that one of the three branches of the unfolded protein response is selectively activated in advanced PCa. This adaptive response activates the phosphorylation of the eukaryotic initiation factor 2-α (P-eIF2α) to reset global protein synthesis to a level that fosters aggressive tumor development and is a marker of poor patient survival upon the acquisition of multiple oncogenic lesions. Using patient-derived xenograft models and an inhibitor of P-eIF2α activity, ISRIB, our data show that targeting this adaptive brake for protein synthesis selectively triggers cytotoxicity against aggressive metastatic PCa, a disease for which presently there is no cure.

AB - Oncogenic lesions up-regulate bioenergetically demanding cellular processes, such as protein synthesis, to drive cancer cell growth and continued proliferation. However, the hijacking of these key processes by oncogenic pathways imposes onerous cell stress that must be mitigated by adaptive responses for cell survival. The mechanism by which these adaptive responses are established, their functional consequences for tumor development, and their implications for therapeutic interventions remain largely unknown. Using murine and humanized models of prostate cancer (PCa), we show that one of the three branches of the unfolded protein response is selectively activated in advanced PCa. This adaptive response activates the phosphorylation of the eukaryotic initiation factor 2-α (P-eIF2α) to reset global protein synthesis to a level that fosters aggressive tumor development and is a marker of poor patient survival upon the acquisition of multiple oncogenic lesions. Using patient-derived xenograft models and an inhibitor of P-eIF2α activity, ISRIB, our data show that targeting this adaptive brake for protein synthesis selectively triggers cytotoxicity against aggressive metastatic PCa, a disease for which presently there is no cure.

UR - http://www.scopus.com/inward/record.url?scp=85046407074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046407074&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aar2036

DO - 10.1126/scitranslmed.aar2036

M3 - Article

C2 - 29720449

AN - SCOPUS:85046407074

VL - 10

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 439

M1 - eaar2036

ER -